Post by PressReleaseon Nov 22, 2022 7:13am
15 Views
Post# 35117966
New Press Release - Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)